The Solution


ELGAN Pharma is developing a therapy that is aimed to prevent the multifactorial visual deterioration of preterm infants.


The therapy is provided locally as eye drops,  it is a combination of compounds that target the complex aspects of the disease. The therapy is based on enhanced drug penetration profile using nano-particulate based formulation. The novelty is in the combination and route of administration, alongside the tailored formulation, these substantiate the company IP coverage.

This site was designed with the
website builder. Create your website today.
Start Now